Arvinas

Youtube Subscribe

Open: 22.24 Close: 21.77 Change: -0.47

Don't invest in Arvinas before reading this automated analysis produce by an AI.

How much time have you spent trying to decide whether investing in Arvinas? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Arvinas, target, …

Concept Map

Semantic Network

Stock Summary

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that.

Today's Summary

Pfizer to pay at least $1 billion to develop, commercialize Arvins investigational breast-cancer therapy. Wall Street analysts predict a 165.07% Upside in Arvinas.

Today's News

Guggenheim Upgrades Arvinas to Buy, Announces $40 price target. Innovation passport designation awarded to Pfizer and Arvinis 1 August 2023. Pfizer to pay at least $1 billion to develop, commercialize Arvins investigational breast-cancer therapy. Wall Street Analysts predict a 165.07% Upside in Arvinas, Inc. (arvn): heres what you should know - november 15, 2023 - zacks.com. Wall Street analysts predict a. 165.7% upside in arvinas. The mean of analysts price targets for Arvin. Arvinas is a biotechnology research company that is “propelling the future with targeted protein degradation” The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE. Arvinas, Inc. (NASDAQ:ARVN) Soars 10.3%: Is further Upside left in the Stock? (Zacks)

Stock Profile

"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut."

Keywords

The game is changing. There is a new strategy to evaluate Arvinas fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Arvinas, target, Inc, price, Pfizer, Wall, Street, and the most common words in the summary are: inc, corp, group, holding, ltd, therapeutic, arvinas, . One of the sentences in the summary was: Pfizer to pay at least $1 billion to develop, commercialize Arvins investigational breast-cancer therapy. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #inc #corp #group #holding #ltd #therapeutic #arvinas.

Read more →

Youtube Subscribe

---